Abstract
To investigate the effect of bone marrow mesenchymal stem cells (MSC) on hematopoietic recovery and acute graft-versus-host disease (GVHD) in a murine allogeneic umbilical cord blood transplantation (allo-UCBT) model. MSCs were obtained from C57/BL mouse bone marrow. The MSC phenotypes were identified by flow cytometry (FCM), and their ability to differentiate into osteoblasts and adipocytes was tested. Once murine allo-UCBT and aGVHD models were established, mice were divided into five groups: (1) total body irradiation (TBI) group, each mouse receiving 0.3 ml sterile saline infusion after TBI and used as control; (2) UCB group, receiving 2 × 106 umbilical cord blood mononuclear cells (UCB-MNC) after TBI; (3) UCB+MSC group, receiving 2 × 106 UCB-MNC and 2 × 107 MSC after TBI; (4) UCB+SC group, receiving 2 × 106 UCB-MNC and 2 × 106 spleen cells after TBI; and (5) UCB+SC+MSC group, receiving 2 × 106 UCB-MNC, 2 × 107 MSC and 2 × 106 spleen cells after TBI. To evaluate the engraftment of HSC, the white blood cells, red blood cells, and platelets counts were tested at different time points after transplantation, and the ratio of chimerism was identified by FCM. The acute GVHD clinical scores, recipient mice survival, and the histopathological analyses were used to evaluate the effect of MSC on acute GVHD. MSCs were successfully obtained in vitro and FCM analysis showed that these cells are highly positive for CD90.2, CD44, and negative for CD34, CD45, and they are capable to differentiate into osteoblasts and adipocytes after being induced. Compared to UCB group, the UCB+MSC mice had shorter duration of myelosuppression and higher percentage of donor-derived cells which was up to 22.87 ± 4.3 % and the white blood cell (WBC), red blood cell (RBC), and platelet counts started to increase by day 6 after transplantation. Moreover, the average survival time for UCB+MSC mice was 25.0 ± 10.55 days, while for the UCB group it was 15.5 ± 12.50 days. The UCB+SC mice showed fatigue, loss of appetite, weight loss, arched back, and hair ruffling on day 13 post transplantation. Approximately 50 % of mice showed skin ulcers, had diarrhea and other manifestations of acute GVHD, and all mice were died within 20 days. Histopathological analysis confirmed grade II–IV GVHD manifestation. In addition to transient weight loss, some UCB+SC+MSC mice developed arched back, hair ruffling, diarrhea and other manifestations of acute GVHD. The clinical scores in UCB+SC+MSC mice with acute GVHD (grade I–II or without GVHD) were lower than UCB+SC group (P < 0.05). Bone marrow MSCs can promote hematopoietic recovery and decrease the incidence of acute GVHD in murine allo-UCBT model.
Similar content being viewed by others
References
Gluckman, E., & Rocha, V. (2009). Cord blood transplantation: State of the art. Haematologica, 94, 451–454.
Frassoni, F., Gualandi, F., Podestà, M., et al. (2008). Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: A phase I/II study. The Lancet Oncology, 9, 812–814.
Szabolcs, P., & Niedzwiecki, D. (2008). Immune reconstitution in children after unrelated cord blood transplantation. Biology of Blood and Marrow Transplantation, 14(1 suppl 1), 66–72.
Komanduri, K. V., John, L. S., de Lima, M., et al. (2007). Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing. Blood, 110(13), 4543–4551.
Takami, A., Mochizuki, K., Asakura, H., et al. (2005). High incidence of cytomegalovirus reactivation in adult recipients of an unrelated cord blood transplant. Haematologica, 90(9), 1290–1292.
Kurtzberg, J., Prasad, V. K., Carter, S. L., et al. (2008). Results of the cord blood transplantation study (COBLT): Clinical outcome of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignancies. Blood, 112(10), 4318–4327.
Gluckman, E. (2000). Current status of umbilical cord blood hematopoietic stem cell transplantation. Experimental Hematology, 28(11), 1197–1205.
Marktel, S., Magnani, Z., Cicer, F., et al. (2003). Immunologic potential of donor lymphocytes expressing a suicide gene for early immune reconstitution after hematopoietic T-cell-depleted stem cell transplantation. Blood, 101(4), 1290–1298.
Cohen, J. L., Boyer, O., Thomas-Vaslin, V., et al. (1999). Suicide gene-mediated modulation of GVHD. Leukaemia & Lymphoma, 34(5–6), 473–480.
Peister, A., Mellad, J. A., Larson, B. L., et al. (2004). Adult stem cells from bone marrow (MSCs) isolated from different strains of inbred mice vary in surface epitopes, rates of proliferation, and differentiation potential. Blood, 103, 1662–1668.
Cooke, K. R., Kobzik, L., Martin, T. R., et al. (1996). An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood, 88, 3230–3239.
Jiang, X. X., Zhang, Y., Liu, B., et al. (2005). Human mesenchymal stem cells inhibit differentiation and function of monocyte derived dendritic cells. Blood, 105(10), 4120–4126.
Di Nicola, M., Carlo-Stella, C., Magni, M., et al. (2002). Human bone marrow stormal cells suppress T lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood, 99(10), 3838–3843.
Krampera, M., Cosmi, L., Angeli, R., et al. (2006). Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells, 24, 386–398.
Sudres, M., Norol, F., & Trenado, A. (2006). Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versus-host disease in mice. Journal of Immunology, 176, 7761–7767.
Bernardo, M. E., Ball, L. M., & Cometa, A. M. (2011). Co-infusion of ex vivo-expanded, parental MSCs prevents life-threatening acute GVHD, but does not reduce the risk of graft failure in pediatric patients undergoing allogeneic umbilical cord blood transplantation. Bone Marrow Transplantation, 46, 200–207.
Meuleman, N., Tondreau, T., & Ahmad, I. (2009). Infusion of mesenchymal stromal cells can aid hematopoietic recovery following allogeneic hematopoietic stem cell myeloablative transplant: A pilot study. Stem Cells and Development, 18, 1247–1252.
Ringdén, O. (2009). Mesenchymal stromal cells as first-line treatment of graft failure after hematopoietic stem cell transplantation. Stem Cells and Development, 18, 1243–1246.
Kim, D. H., Yoo, K. H., Yim, Y. S., et al. (2006). Cotransplanted bone marrow derived mesenchymal stem cells (MSC) enhanced engraftment of hematopoietic stem cells in a MSC-dose dependent manner in NOD/SCID mice. Journal of Korean Medical Science, 21, 1000–1004.
Joo, S. Y., Cho, K. A., Jung, Y. J., et al. (2010). Mesenchymal stromal cells inhibit graft-versus-host disease of mice in a dose-dependent manner. Cytotherapy, 12, 361–370.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Li, Z.Y., Wang, C.Q., Lu, G. et al. Effects of Bone Marrow Mesenchymal Stem Cells on Hematopoietic Recovery and Acute Graft-Versus-Host Disease in Murine Allogeneic Umbilical Cord Blood Transplantation Model. Cell Biochem Biophys 70, 115–122 (2014). https://doi.org/10.1007/s12013-014-9866-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12013-014-9866-y